Abstract
The search for novel, effective, and safe psychotropic medications for use in children and adolescents is an ongoing journey. Specifically, several atypical antipsychotics have received FDA indications for use in children and adolescents, although carry the risk of potentially serious side effects such as extrapyramidal symptoms, tardive dyskinesia, weight gain, metabolic syndrome, and symptoms of hyperprolactinemia. Three newer antipsychotics – asenapine, iloperidone, and lurasidone – have been considered by some as alternatives to use in children and adolescents with various psychiatric conditions. However, the data on the use of these medications in this population is limited. We review the current literature regarding the use of these agents in children and adolescents. Although these medications may have similar properties to current agents with approved indications, there is not sufficient evidence at this time to recommend their use in children and adolescents. More research is needed regarding the efficacy, safety, and tolerability of these medications in the pediatric population.
Keywords: Adolescents, antipsychotics, asenapine, children, iloperidone, lurasidone.
Current Psychopharmacology
Title:Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population
Volume: 3
Author(s): Michael Shapiro, Mariam Rahmani, Adrienne Eisner and Mathew Nguyen
Affiliation:
Keywords: Adolescents, antipsychotics, asenapine, children, iloperidone, lurasidone.
Abstract: The search for novel, effective, and safe psychotropic medications for use in children and adolescents is an ongoing journey. Specifically, several atypical antipsychotics have received FDA indications for use in children and adolescents, although carry the risk of potentially serious side effects such as extrapyramidal symptoms, tardive dyskinesia, weight gain, metabolic syndrome, and symptoms of hyperprolactinemia. Three newer antipsychotics – asenapine, iloperidone, and lurasidone – have been considered by some as alternatives to use in children and adolescents with various psychiatric conditions. However, the data on the use of these medications in this population is limited. We review the current literature regarding the use of these agents in children and adolescents. Although these medications may have similar properties to current agents with approved indications, there is not sufficient evidence at this time to recommend their use in children and adolescents. More research is needed regarding the efficacy, safety, and tolerability of these medications in the pediatric population.
Export Options
About this article
Cite this article as:
Shapiro Michael, Rahmani Mariam, Eisner Adrienne and Nguyen Mathew, Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population, Current Psychopharmacology 2014; 3 (2) . https://dx.doi.org/10.2174/221155600302150302112302
DOI https://dx.doi.org/10.2174/221155600302150302112302 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Therapeutic Macromolecular Iron Chelators
Current Medicinal Chemistry Safety Limits of Antidepressant Use Plus Combinations: Focus on Cardiovascular Function
Current Drug Metabolism Long Acting Betaxolol Ocular Inserts based on Polymer Composite
Current Drug Delivery Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
Current Vascular Pharmacology Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways
Current Diabetes Reviews Clozapine Safety, 35 Years Later
Current Drug Safety New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Role of the Peroxynitrite - Poly (ADP-Ribose) Polymerase Pathway in the Pathogenesis of Liver Injury
Current Pharmaceutical Design Laparoscopic Surgery for Pheochromocytoma and Paraganglioma Removal: A Retrospective Analysis of Anaesthetic Management
Current Hypertension Reviews Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Systematic Review
Current Pediatric Reviews Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Bioavailability Through PepT1: The Role of Computer Modelling in Intelligent Drug Design
Current Computer-Aided Drug Design A Possible Placental Factor for Preeclampsia: sFlt-1
Current Medicinal Chemistry Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology Magnesium and Anaesthesia
Current Drug Targets Research Advances in Neuroblastoma Immunotherapy
Current Pediatric Reviews Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure
Current Drug Safety Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians
Current Drug Safety